A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer.

Jamunarani Veeraraghavan Carolina Gutierrez Carmine De Angelis Robert Davis Nicholas Wang Tomás Pascual Pier Selenica Katherine Sanchez Hiroaki Nitta Monesh Kapadia Anne C Pavlick Patricia Galván Brent N Rexer Andres Forero-Torres Rita Nanda Anna Maria V Storniolo Ian E Krop Matthew P Goetz Julie R Nangia Antonio C Wolff Jorge S Reis-Filho Jorge Sergio Reis-Filho Susan G Hilsenbeck Aleix Prat C Kent Osborne Rachel Schiff Mothaffar F Rimawi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our multiparameter classifier differentially identifies patients who may benefit from HER2-targeted therapy alone from those who need chemotherapy and predicts pCR to anti-HER2 therapy alone comparable to chemotherapy plus dual anti-HER2 therapy in unselected patients.

Keyphrases

locally advanced
rectal cancer
end stage renal disease
ejection fraction
flow cytometry
newly diagnosed
squamous cell carcinoma
chronic kidney disease
peritoneal dialysis
radiation therapy
genome wide
stem cells
lymph node
dna methylation